Authors,Author(s) ID,Title,Year,Source tittle,Cited by,DOI,Country,Document Type,City,Access Type,aggregationType,EID
Gulati R.,,Individualized estimates of overdiagnosis in screen-detected prostate cancer,2014,Journal of the National Cancer Institute,29,10.1093/jnci/djt367,United States,Article,Seattle,1,Journal,2-s2.0-84893845633
Siegel R.,,"Cancer statistics, 2014",2014,CA Cancer Journal for Clinicians,10069,10.3322/caac.21208,United States,Article,Atlanta,0,Journal,2-s2.0-84892805731
Grenabo Bergdahl A.,,Incidence of prostate cancer after termination of screening in a population-based randomised screening trial,2013,European Urology,28,10.1016/j.eururo.2013.05.024,Sweden,Review,Gothenburg,0,Journal,2-s2.0-84885419324
Carter H.,,Early detection of prostate cancer: AUA guideline,2013,Journal of Urology,606,10.1016/j.juro.2013.04.119,United States,Article,Linthicum,0,Journal,2-s2.0-84880005911
Etzioni R.,,Influence of study features and methods on overdiagnosis estimates in breast and prostate cancer screening,2013,Annals of Internal Medicine,89,10.7326/0003-4819-158-11-201306040-00008,United States,Article,Seattle,0,Journal,2-s2.0-84878716848
Qaseem A.,,Screening for prostate cancer: A guidance statement from the clinical guidelines committee of the American college of physicians,2013,Annals of Internal Medicine,189,10.7326/0003-4819-158-10-201305210-00633,,Review,,0,Journal,2-s2.0-84878101564
Gulati R.,,Comparative effectiveness of alternative prostate-specific antigen-based prostate cancer screening strategies: Model estimates of potential benefits and harms,2013,Annals of Internal Medicine,96,10.7326/0003-4819-158-3-201302050-00003,United States,Article,Seattle,0,Journal,2-s2.0-84873364644
Resnick M.J.,,Long-term functional outcomes after treatment for localized prostate cancer,2013,New England Journal of Medicine,552,10.1056/NEJMoa1209978,United States;United States,Article,Nashville;Nashville,0,Journal,2-s2.0-84873050980
Etzioni R.,,The prostate cancer conundrum revisited: Treatment changes and prostate cancer mortality declines,2012,Cancer,91,10.1002/cncr.27594,United States,Article,Seattle,0,Journal,2-s2.0-84869506047
Vickers A.,,Individualized estimation of the benefit of radical prostatectomy from the Scandinavian Prostate Cancer Group randomized trial,2012,European Urology,82,10.1016/j.eururo.2012.04.024,United States,Article,New York,0,Journal,2-s2.0-84862877628
Wilt T.,,Radical prostatectomy versus observation for localized prostate cancer,2012,New England Journal of Medicine,1299,10.1056/NEJMoa1113162,United States,Article,Minneapolis,0,Journal,2-s2.0-84864008031
Gulati R.,,The impact of PLCO control arm contamination on perceived PSA screening efficacy,2012,Cancer Causes and Control,48,10.1007/s10552-012-9951-8,United States,Article,Seattle,0,Journal,2-s2.0-84862495438
Miller A.,,New data on prostate-cancer mortality after PSA screening,2012,New England Journal of Medicine,39,10.1056/NEJMe1200185,Canada,Editorial,Toronto,0,Journal,2-s2.0-84858266832
Schr√∂der F.H.,,Prostate-cancer mortality at 11 years of follow-up,2012,New England Journal of Medicine,916,10.1056/NEJMoa1113135,Netherlands,Article,Rotterdam,0,Journal,2-s2.0-84858212484
Tasian G.,,"Prostate specific antigen screening for prostate cancer: Knowledge of, attitudes towards, and utilization among primary care physicians",2012,Urologic Oncology: Seminars and Original Investigations,32,10.1016/j.urolonc.2009.12.019,United States,Article,San Francisco,0,Journal,2-s2.0-84857640743
Andriole G.L.,,"Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: Mortality results after 13 years of follow-up",2012,Journal of the National Cancer Institute,720,10.1093/jnci/djr500,United States,Article,St. Louis,1,Journal,2-s2.0-84856200634
Ganz P.A.,,National Institutes of Health State-of-the-Science Conference: role of active surveillance in the management of men with localized prostate cancer.,2012,Annals of internal medicine,146,,United States,Conference Paper,Los Angeles,0,Journal,2-s2.0-84862626235
Moyer V.,,Screening for prostate cancer: U.S. preventive services task force recommendation statement,20120717,Annals of Internal Medicine,1399,10.7326/0003-4819-157-2-201207170-00459,United States,Review,Houston,0,Journal,2-s2.0-84863961968
Chou R.,,"Prostate cancer screening - The evidence, the recommendations, and the clinical implications",2011,JAMA - Journal of the American Medical Association,35,10.1001/jama.2011.1891,United States,Note,Portland,0,Journal,2-s2.0-84555178261
Gulati R.,,Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates,2011,Journal of Clinical Epidemiology,40,10.1016/j.jclinepi.2011.06.011,United States,Article,Seattle,0,Journal,2-s2.0-80055019354
Hanley J.,,Measuring mortality reductions in cancer screening trials,2011,Epidemiologic Reviews,29,10.1093/epirev/mxq021,Canada,Article,Montreal,1,Journal,2-s2.0-79960523327
Kenfield S.,,Smoking and prostate cancer survival and recurrence,2011,JAMA - Journal of the American Medical Association,156,10.1001/jama.2011.879,United States,Article,Boston,1,Journal,2-s2.0-79959392796
Boorjian S.,,Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: The impact of time from surgery to recurrence,2011,European Urology,183,10.1016/j.eururo.2011.02.026,United States,Article,Rochester,0,Journal,2-s2.0-79955608101
Bill-Axelson A.,,Radical prostatectomy versus watchful waiting in early prostate cancer,2011,New England Journal of Medicine,664,10.1056/NEJMoa1011967,Sweden;Sweden,Article,Uppsala;Gothenburg,0,Journal,2-s2.0-79955705831
Gulati R.,,What if I don't treat my PSA-detected prostate cancer? Answers from three natural history models,2011,Cancer Epidemiology Biomarkers and Prevention,34,10.1158/1055-9965.EPI-10-0718,United States,Article,Seattle,1,Journal,2-s2.0-79955770008
Drazer M.,,Population-based patterns and predictors of prostate-specific antigen screening among older men in the United States,2011,Journal of Clinical Oncology,88,10.1200/JCO.2010.31.9004,United States;United States,Article,Boston;Chicago,0,Journal,2-s2.0-79955588383
Gulati R.,,Calibrating disease progression models using population data: A critical precursor to policy development in cancer control,2010,Biostatistics,31,10.1093/biostatistics/kxq036,United States,Article,Seattle,1,Journal,2-s2.0-77953172727
Vickers A.J.,,Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: Case-control study,2010,BMJ (Online),161,10.1136/bmj.c4521,United States,Article,New York,1,Journal,2-s2.0-77956811462
Huang G.,,Health Related Quality of Life for Men Treated for Localized Prostate Cancer With Long-Term Followup,2010,Journal of Urology,96,10.1016/j.juro.2010.02.013,United States,Article,Pittsburgh,0,Journal,2-s2.0-77951877467
Wolf A.M.D.,,American Cancer Society guideline for the early detection of prostate cancer: Update 2010,2010,CA Cancer Journal for Clinicians,600,10.3322/caac.20066,United States,Review,Charlottesville,0,Journal,2-s2.0-77949363162
Cooperberg M.,,Time trends and local variation in primary treatment of localized prostate cancer,2010,Journal of Clinical Oncology,708,10.1200/JCO.2009.26.0133,United States,Article,San Francisco,0,Journal,2-s2.0-77949898163
Sun L.,,Men Older Than 70 Years Have Higher Risk Prostate Cancer and Poorer Survival in the Early and Late Prostate Specific Antigen Eras,2009,Journal of Urology,58,10.1016/j.juro.2009.07.034,United States,Article,Durham,0,Journal,2-s2.0-70350468855
Roobol M.J.,,Prostate Cancer Mortality Reduction by Prostate-Specific Antigen-Based Screening Adjusted for Nonattendance and Contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC),2009,European Urology,177,10.1016/j.eururo.2009.07.018,Netherlands,Article,Rotterdam,0,Journal,2-s2.0-69249209651
Welch H.,,Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005,2009,Journal of the National Cancer Institute,411,10.1093/jnci/djp278,United States;United States,Article,Lebanon;White River Junction,1,Journal,2-s2.0-70349941075
Schaeffer E.,,Prostate Specific Antigen Testing Among the Elderly-When To Stop?,2009,Journal of Urology,53,10.1016/j.juro.2008.11.117,United States,Article,Baltimore,0,Journal,2-s2.0-62049083169
Fesinmeyer M.,,Effect of population trends in body mass index on prostate cancer incidence and mortality in the United States,2009,Cancer Epidemiology Biomarkers and Prevention,21,10.1158/1055-9965.EPI-08-0784,United States,Article,Seattle,1,Journal,2-s2.0-64549159838
Draisma G.,,Lead time and overdiagnosis in prostate-specific antigen screening: Importance of methods and context,2009,Journal of the National Cancer Institute,528,10.1093/jnci/djp001,Netherlands,Article,Rotterdam,1,Journal,2-s2.0-64949135826
Trock B.,,Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy,2008,JAMA - Journal of the American Medical Association,491,10.1001/jama.299.23.2760,United States,Article,Baltimore,1,Journal,2-s2.0-45349084317
Etzioni R.,,Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: A surveillance modeling approach,2008,Medical Decision Making,70,10.1177/0272989X07312719,United States,Article,Seattle,0,Journal,2-s2.0-44049096242
Sanda M.G.,,Quality of life and satisfaction with outcome among prostate-cancer survivors,2008,New England Journal of Medicine,1585,10.1056/NEJMoa074311,United States;United States,Article,Boston;Boston,0,Journal,2-s2.0-40949147326
Etzioni R.,,Quantifying the role of PSA screening in the US prostate cancer mortality decline,2008,Cancer Causes and Control,256,10.1007/s10552-007-9083-8,United States,Article,Seattle,0,Journal,2-s2.0-38949085322
Mariotto A.,,Reconstructing PSA testing patterns between black and white men in the US from medicare claims and the National Health Interview Survey,2007,Cancer,61,10.1002/cncr.22607,United States,Article,Bethesda,1,Journal,2-s2.0-34247563274
Walter L.,,PSA screening among elderly men with limited life expectancies,2006,Journal of the American Medical Association,212,10.1001/jama.296.19.2336,United States;United States,Article,San Francisco;,1,Journal,2-s2.0-33750978664
Tsodikov A.,,A population model of prostate cancer incidence,2006,Statistics in Medicine,40,10.1002/sim.2257,United States,Article,Davis,0,Journal,2-s2.0-33746903130
Ross K.,,Estimation of treatment benefits when PSA screening for prostate cancer is discontinued at different ages,2005,Urology,17,10.1016/j.urology.2005.05.030,,Article,,0,Journal,2-s2.0-27744558577
Pinsky P.,,"Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial",2005,Journal of Urology,57,10.1097/01.ju.0000152697.25708.71,United States;United States,Conference Paper,Bethesda;Bethesda,0,Journal,2-s2.0-13744253438
Thompson I.,,The influence of finasteride on the development of prostate cancer,2003,New England Journal of Medicine,2133,10.1056/NEJMoa030660,United States,Article,San Antonio,0,Journal,2-s2.0-0037812658
Etzioni R.,,Asymptornatic incidence and duration of prostate cancer,1998,American Journal of Epidemiology,102,10.1093/oxfordjournals.aje.a009698,United States,Article,Seattle,1,Journal,2-s2.0-0032531427
